Jump to content

CUV - CLINUVEL PHARMACEUTICALS LIMITED


colaiscute

Recommended Posts

  • Replies 51.4k
  • Created
  • Last Reply

Top Posters In This Topic

  • royco

    2914

  • Kiwi1

    1702

  • seeva222

    1669

  • Reality Check

    1771

Top Posters In This Topic

Posted Images

Would it be an exaggeration or over the top at all to believe that the potential of this essential, proven beyond doubt cancer preventing photoprotective (prophylactic) and therapeutic (TOTALLY DERISKED) drug Scenesse is almost limitless and beyond compare??

 

Fact is every human being on this planet benefits greatly by having high levels of Eumelanin flowing throughout their skin.

 

“â€Skin cancer is the most common cancer in the United States and worldwide.â€â€

 

1 in 5 Americans will develop skin cancer by the age of 70.

 

More than 2 people die of skin cancer in the U.S. every hour.

 

Having 5 or more sunburns doubles your risk for melanoma.

 

#freeScenessenow :B):

Link to comment
Share on other sites

Yes interesting. I came across an article on Lupis the other day by chance and thought the same thing. CUV has tried Scenesse with actinic keratosis, Solar urticaria, Hailey's and no doubt other conditions. I imagine there will be a relatively quick process in mind should specialists want access to the drug for their patients. A medicinal oinment / cream should be useful across many skin conditions where UV damage could be more harmful or where people are more sensitive. Next two years with CUV should be very interesting. GLTA
Link to comment
Share on other sites

We all don't really think the 30 approved US dermatology centers are just to treat EPP patients, right? I would imagine Clinuvel has a grand vision to treat various indications with Scenesse. Should be an interesting next 24 months - and hopefully quite profitable!
Link to comment
Share on other sites

Australia’s Clinuvel expands R&D presence as it builds out pipeline for DNA repair

 

https://www.bioworld.com/articles/497724-au...-for-dna-repair

 

“Many investors don’t understand our approach. But to me it’s all about laying a foundation of a company that survives over time,†Wolgen said.

 

“Now that the EPP indication is done, we can finally open the R&D spectrum, because it’s a family of hormones and it does a multitude of things. We’ve always known that, but we just didn’t want to do it in parallel; we did it sequentially.

 

Reversing sun damage was always the key characteristic of Scenesse, he said. In early trials in 2006, the drug was given to 82 Australian volunteers in Queensland, where biopsies taken from patients with sun damage saw reversal of that damage with treatment.

 

Wolgen said it would have been impossible to get approval for the broad sun damage indication because there wasn’t a disease attached to it, so the EPP route was the first stage of the company’s journey.

 

Two more indications will be announced in the coming weeks, he said."

Link to comment
Share on other sites

The next 12 months should be fun. Quarterly reports showing 50-100% YOY revenue growth, combined with continued news of new indication possibilities.

 

It's all up from here. Good times!

 

I just increased my 20% holding reduction to a price target of $40. You may have no shares before.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...